Sign up with Google
Sign in with Zoho
Antibody Drug Conjugates Market Size
Straits Research, a leading provider of market intelligence and advisory services, has published its latest report on the global Antibody Drug Conjugates (ADC) market, highlighting substantial growth potential driven by technological innovation and increasing oncology applications.
According to Straits Research, the global antibody drug conjugates market size was valued at USD 13.63 billion in 2025 and is projected to reach USD 34.87 billion by 2034, growing at a CAGR of 11.04% during the forecast period (2026–2034). Antibody drug conjugates represent a highly targeted class of biopharmaceutical drugs that combine monoclonal antibodies with cytotoxic agents, enabling precise delivery of chemotherapy drugs directly to cancer cells while minimizing damage to healthy tissues. This targeted therapeutic approach is gaining significant traction in oncology treatment protocols worldwide.
Key Development in the Antibody Drug Conjugates Market
The ADC market has witnessed significant developments in recent years, marked by strategic collaborations, product launches, and technological advancements. Pharmaceutical companies are increasingly forming partnerships to leverage complementary expertise in antibody engineering, linker chemistry, and payload development.
Several next-generation ADCs are entering clinical and commercial stages, offering improved targeting capabilities and reduced off-target effects. Companies are also focusing on expanding the indications of existing ADC drugs beyond their initial approvals, thereby maximizing their market potential.
Furthermore, advancements in biomarker identification are enabling more precise patient selection, enhancing treatment outcomes and driving adoption among healthcare providers. The integration of personalized medicine approaches with ADC therapies is expected to redefine cancer treatment paradigms in the coming years.
Segmentation Analysis of the Antibody Drug Conjugates Market
- By Product Type
- Adcetris
- Kadcyla
- Enhertu
- Padcev
- Trodelvy
- Others
- By Application
- Blood Cancer
- Breast Cancer
- Urothelial Cancer
- Lung Cancer
- Others
- By Target
- CD33
- HER2
- CD30
- TROP2
- Others
Top Key Players
- Hoffmann-La Roche Ltd.
- Daiichi Sankyo
- Pfizer Inc.
- Gilead Sciences
- AstraZeneca
- AbbVie Inc.
- ADC Therapeutics
- Genmab A/S
- Astellas Pharma Inc.
- RemeGen Co., Ltd.
- GSK plc
- Takeda Pharmaceuticals
- Hansoh Pharmaceutical Group Company Limited
- Eli Lilly and Company
- Bristol-Myers Squibb Company
These companies are at the forefront of innovation in the ADC market, focusing on expanding their product pipelines, enhancing manufacturing capabilities, and entering strategic collaborations to strengthen their competitive positioning.
About Straits Research
Straits Research is a top provider of business intelligence, specializing in research, analytics, and advisory services. The company is committed to delivering in-depth insights through comprehensive reports, helping clients make informed strategic decisions. With a strong focus on data accuracy and industry expertise, Straits Research serves a diverse range of industries worldwide.
Contact Us
Email: [email protected]
